Comparative metabolism as a key driver of wildlife species sensitivity to human and veterinary pharmaceuticals
Tóm tắt
Human and veterinary drug development addresses absorption, distribution, metabolism, elimination and toxicology (ADMET) of the Active Pharmaceutical Ingredient (API) in the target species. Metabolism is an important factor in controlling circulating plasma and target tissue API concentrations and in generating metabolites which are more easily eliminated in bile, faeces and urine. The essential purpose of xenobiotic metabolism is to convert lipid-soluble, non-polar and non-excretable chemicals into water soluble, polar molecules that are readily excreted. Xenobiotic metabolism is classified into Phase I enzymatic reactions (which add or expose reactive functional groups on xenobiotic molecules), Phase II reactions (resulting in xenobiotic conjugation with large water-soluble, polar molecules) and Phase III cellular efflux transport processes. The human–fish plasma model provides a useful approach to understanding the pharmacokinetics of APIs (e.g. diclofenac, ibuprofen and propranolol) in freshwater fish, where gill and liver metabolism of APIs have been shown to be of importance. By contrast, wildlife species with low metabolic competency may exhibit zero-order metabolic (pharmacokinetic) profiles and thus high API toxicity, as in the case of diclofenac and the dramatic decline of vulture populations across the Indian subcontinent. A similar threat looms for African Cape Griffon vultures exposed to ketoprofen and meloxicam, recent studies indicating toxicity relates to zero-order metabolism (suggesting P450 Phase I enzyme system or Phase II glucuronidation deficiencies). While all aspects of ADMET are important in toxicity evaluations, these observations demonstrate the importance of methods for predicting API comparative metabolism as a central part of environmental risk assessment.
Từ khóa
Tài liệu tham khảo
Harborne JB, 1993, Introduction to ecological biochemistry, 4
Nelson DR, 1998, Metazoan cytochrome P450 evolution, Comp. Biochem. Physiol., 121, 15
Ronis MJJ, 1989, The microsomal monooxygenases of birds, Rev. Biochem. Toxicol., 10, 301
Walker CH, 2012, Principles of ecotoxicology, 4
Walker CH, 1980, Species differences in some hepatic microsomal enzymes that metabolise xenobiotics, Prog. Drug Metab., 5, 118
Walker CH, 1981, Progress in pesticide biochemistry, 287
Buhler DR, 1998, Rainbow trout cytochrome P450s: purification, molecular aspects, metabolic activity, induction and role in environmental monitoring, Comp. Biochem. Physiol., 121, 107
Celander M, 1993, Induction of cytochrome P450 1A1 and conjugating enzymes in rainbow trout (Oncorhynchus mykiss) liver: a time course study, Comp. Biochem. Physiol. A, 106, 343
Solé M, 2009, Xenobiotic metabolism markers in marine fish with different trophic strategies and their relationship to ecological variables, Comp. Biochem. Physiol. C, 149, 83
Parkinson A, 1996, Casarett and Doull's toxicology, the basic science of poisons, unit 2, 133
Obach RS, 1997, The prediction of human pharmacokinetics parameters from preclinical and in vitro metabolism data, J. Pharmacol. Exp. Ther., 283, 46
Grosser T, 2011, Goodman and Gilman's the pharmacological basis of therapeutics, 11, 959
Schmitt H, 2010, Recommendations on the environmental risk assessment of pharmaceuticals: effect characterization, Int. Environ. Assess. Manag., 6, 588, 10.1897/IEAM_2009-053.1
Küster A, 2010, Environmental risk assessment of human pharmaceuticals in the European Union: a case study with the beta-blocker atenolol, Int. Environ. Assess. Manag., 6, 514, 10.1897/IEAM_2009-050.1
Verbrugge LA, 2001, Catalytic and immunochemical properties of hepatic cytochrome P450 1A in three avian species treated with beta-naphthoflavone or isosafrole, Comp. Biochem. Physiol. C, 130, 67
Kubota A, 2009, Alkoxyresorufin (methoxy-, ethoxy-, pentoxy- and benzyloxyresorufin) O-dealkylase activities by in vitro-expressed cytochrome P450 1A4 and 1A5 from common cormorant (Phalacrocorax carbo), Comp. Biochem. Physiol. C, 149, 544